Bibiliografía

1. O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011 Feb;9(2):305-11. [PubMed]

2. Sahut D'Izarn M, Caumont Prim A, Planquette B, Revel MP, Avillach P, Chatellier G, et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study. J Thromb Haemost. 2012 Oct;10(10):2032-8. [PubMed]

3. Connolly GC, Menapace L, Safadjou S, Francis CW, Khorana AA. Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. Clin Lung Cancer. 2013 Nov;14(6):713-8. [PubMed]

4. Khorana AA, O'Connell C, Agnelli G, Liebman HA, Lee AY; Subcommittee on Hemostasis and Malignancy of the SSC of the ISTH. Incidental venous thromboembolism in oncology patients. J Thromb Haemost. 2012 Dec;10(12):2602-4. [PubMed]

5. Meyer HJ, Wienke A, Surov A. Incidental pulmonary embolism in oncologic patients-a systematic review and meta-analysis. Support Care Cancer. 2021 Mar;29(3):1293-302. [PubMed]

6. Dentali F, Ageno W, Becattini C, Galli L, Gianni M, Riva N, Imberti D, Squizzato A, Venco A, Agnelli G. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010 Jun;125(6):518-22. [PubMed]

7. Sun JM, Kim TS, Lee J, Park YH, Ahn JS, Kim H, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer. 2010 Sep;69(3):330-6. [PubMed]

8. Font C, Farrús B, Vidal L, Caralt TM, Visa L, Mellado B, et al. Incidental versus symptomatic venous thrombosis in cancer: a prospective observational study of 340 consecutive patients. Ann Oncol. 2011 Sep;22(9):2101-6. [PubMed]

9. Shinagare AB, Okajima Y, Oxnard GR, Dipiro PJ, Johnson BE, Hatabu H, Nishino M. Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism. Lung Cancer. 2012 Nov;78(2):161-6. [PubMed]

10. Van Es N, Bleker SM, Di Nisio M. Cancer-associated unsuspected pulmonary embolism. Thromb Res. 2014 May;133 Suppl 2:S172-8. [PubMed]

11. Farrell C, Jones M, Girvin F, Ritchie G, Murchison JT. Unsuspected pulmonary embolism identified using multidetector computed tomography in hospital outpatients. Clin Radiol. 2010 Jan;65(1):1-5. PMID: 20103414. [PubMed]

12. Browne AM, Cronin CG, English C, NiMhuircheartaigh J, Murphy JM, Bruzzi JF. Unsuspected pulmonary emboli in oncology patients undergoing routine computed tomography imaging. J Thorac Oncol. 2010 Jun;5(6):798-803. [PubMed]

13. Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011 Aug;106(2):371-8. [PubMed]

14. Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, et al. Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15;117(16):3860-6. [PubMed]

15. Callejas MF, Errázuriz JI, Castillo F, Otárola C, Riquelme C, Ortega C, et al. Incidental venous thromboembolism detected by PET-CT in patients with cancer: prevalence and impact on survival rate. Thromb Res. 2014 May;133(5):750-5. [PubMed]

16. Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost. 2010 Aug;8(8):1879-81. [PubMed]

17. Tiseo M, Bersanelli M, Pesenti Barili M, Bartolotti M, De Luca G, Gelsomino F, et al. Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients. Tumori. 2012 Sep-Oct;98(5):594-600. [PubMed]

18. Tresoldi S, Flor N, Luciani A, Lombardi MA, Colombo B, Cornalba G. Contrast enhanced chest-MDCT in oncologic patients. Prospective evaluation of the prevalence of incidental pulmonary embolism and added value of thin reconstructions. Eur Radiol. 2015 Nov;25(11):3200-6. [PubMed]

19. Den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011 Jun 10;29(17):2405-9. [PubMed]

20. Van der Hulle T, den Exter PL, Planquette B, Meyer G, Soler S, Monreal M, et al. Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. J Thromb Haemost. 2016 Jan;14(1):105-13. [PubMed]

21. Den Exter PL, Kroft LJ, van der Hulle T, Klok FA, Jiménez D, Huisman MV. Embolic burden of incidental pulmonary embolism diagnosed on routinely performed contrast-enhanced computed tomography imaging in cancer patients. J Thromb Haemost. 2013 Aug;11(8):1620-2. [PubMed]

22. Spirk D, Sebastian T, Barco S, Banyai M, Beer JH, Mazzolai L, et al. Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWIss Venous ThromboEmbolism Registry (SWIVTER). Thromb Haemost. 2021 May;121(5):641-9. [PubMed]

23. Wysokinska EM, Houghton DE, Vlazny DT, Ashrani AA, Froehling DA, Meverden R, et al. Incidental pulmonary embolism in cancer and noncancer patients: Prospective cohort study. Eur J Haematol. 2023 Jan;110(1):88-98. [PubMed]

24. Barca-Hernando M, López-Ruz S, Marín-Romero S, Elías-Hernández T, Otero-Candelera R, Jara-Palomares L. Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism. Front Cardiovasc Med. 2023 May 19;10:1118385. [PubMed]

25. Font C, Carmona-Bayonas A, Beato C, Reig Ò, Sáez A, Jiménez-Fonseca P, et al.; Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J. 2017 Jan 4;49(1):1600282. [PubMed]

26. Peris M, López-Núñez JJ, Maestre A, Jiménez D, Muriel A, Bikdeli B, et al.; RIETE Investigators. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism. Eur Respir J. 2021 Jul 1;58(1):2002723. [PubMed]

27. García Adrián S, González AR, de Castro EM, Olmos VP, Morán LO, Del Prado PM, et al. Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis. Eur J Intern Med. 2022 Nov;105:30-7. [PubMed]

28. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-23. [PubMed]

29. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, García D, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-24. [PubMed]

30. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al.; Caravaggio Investigators. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020 Apr 23;382(17):1599-607. [PubMed]

31. Caiano L, Carrier M, Marshall A, Young AM, Ageno W, Delluc A, Wang TF. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 Oct;19(10):2468-79. [PubMed]

32. Barca-Hernando M, López-Ruz S, Marín-Romero S, García-García V, Elías-Hernández T, Otero-Candelera R, et al. Risk of recurrent cancer-associated thrombosis after discontinuation of anticoagulant therapy. Res Pract Thromb Haemost. 2023 Mar 10;7(2):100115.[PubMed]

33. Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, et al.; UPE investigators. Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. J Clin Oncol. 2019 Jul 10;37(20):1713-20. [PubMed]

34. Qdaisat A, Wechsler AH, Cruz Carreras MT, Menéndez JR, Lipe D, Highsmith EA, et al. Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism. Cancers (Basel). 2022 Sep 17;14(18):4510. [PubMed]

35. Guman NAM, Kaptein FHJ, Lohle SB, Mairuhu ATA, Klok FA, Huisman MV, et al. Discharge from the emergency department and outpatient clinic in cancer patients with acute symptomatic and incidental pulmonary embolism: A multicenter retrospective cohort study. Thromb Res. 2024 Jan;233:181-8. [PubMed]

36. Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ. Anticoagulant treatment for subsegmental pulmonary embolism. Cochrane Database Syst Rev. 2020 Feb 7;2(2):CD010222. [PubMed]

37. Bariteau A, Stewart LK, Emmett TW, Kline JA. Systematic Review and Meta-analysis of Outcomes of Patients With Subsegmental Pulmonary Embolism With and Without Anticoagulation Treatment. Acad Emerg Med. 2018 Jul;25(7):828-35. [PubMed]

38. Carrier M, Righini M, Wells PS, Perrier A, Anderson DR, Rodger MA, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010 Aug;8(8):1716-22. [PubMed]

39. Den Exter PL, van Es J, Klok FA, Kroft LJ, Kruip MJ, Kamphuisen PW, et al. Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism. Blood. 2013 Aug 15;122(7):1144-9; quiz 1329. [PubMed]

40. Hirao-Try Y, Vlazny DT, Meverden R, Houghton DE, Casanegra AI, Froehling DA, et al. Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome. J Thromb Thrombolysis. 2022 Jul;54(1):82-90. [PubMed]

41. Di Nisio M, Carrier M. Incidental venous thromboembolism: is anticoagulation indicated? Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):121-7. [PubMed]

42. Rodríguez-Cobo A, Fernández-Capitán C, Tung-Chen Y, Salgueiro-Origlia G, Ballaz A, Bortoluzzi C, et al.; The Riete Investigators. Clinical Significance and Outcome in Patients with Asymptomatic Versus Symptomatic Subsegmental Pulmonary Embolism. J Clin Med. 2023 Feb 18;12(4):1640. [PubMed]

43. Le Gal G, Kovacs MJ, Bertoletti L, Couturaud F, Dennie C, Hirsch AM, et al.; SSPE Investigators. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation : A Multicenter Prospective Cohort Study. Ann Intern Med. 2022 Jan;175(1):29-35. [PubMed]

44. Galanaud JP, Sevestre MA, Pernod G, Genty C, Richelet S, Kahn SR, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost. 2017 May;15(5):907-16. [PubMed]

45. Dentali F, Pegoraro S, Barco S, di Minno MND, Mastroiacovo D, Pomero F, et al. Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. J Thromb Haemost. 2017 Sep;15(9):1757-63. [PubMed]

46. Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, Macías Montero R, Martínez-Marín V, Pachón Olmos V, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020 Feb;22(2):171-86. [PubMed]

47. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10;38(5):496-520. [PubMed]

48. Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021 Aug 2:S0012-3692(21)01506-3. [PubMed]

49. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al.; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-e347. [PubMed]

50. Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, et al.; ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023 May;34(5):452-67. [PubMed]

51. Khorana AA, Rubens D, Francis CW. Screening high-risk cancer patients for VTE: a prospective observational study. Thromb Res. 2014 Dec;134(6):1205-7. [PubMed]

52. Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Hirayama M, Tsuji Y. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. BMC Cancer. 2017 May 19;17(1):351. [PubMed]